Alaunos Therapeutics, Inc.
TCRT
$1.48
-$0.02-1.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.00K | 6.00K | 6.00K | 5.00K | 15.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.00K | 6.00K | 6.00K | 5.00K | 15.00K |
| Cost of Revenue | 1.38M | 4.90M | 9.90M | 16.28M | 18.45M |
| Gross Profit | -1.38M | -4.89M | -9.90M | -16.27M | -18.44M |
| SG&A Expenses | 6.04M | 8.61M | 10.67M | 12.22M | 12.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.42M | 13.51M | 20.57M | 28.50M | 31.17M |
| Operating Income | -7.42M | -13.50M | -20.56M | -28.49M | -31.15M |
| Income Before Tax | -11.78M | -19.13M | -26.77M | -35.14M | -36.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.78 | -19.13 | -26.77 | -35.14 | -36.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.78M | -19.13M | -26.77M | -35.14M | -36.46M |
| EBIT | -7.42M | -13.50M | -20.56M | -28.49M | -31.15M |
| EBITDA | -7.17M | -12.58M | -18.94M | -26.18M | -28.39M |
| EPS Basic | -7.36 | -11.95 | -16.73 | -21.97 | -23.22 |
| Normalized Basic EPS | -2.81 | -5.12 | -8.20 | -11.48 | -13.00 |
| EPS Diluted | -7.96 | -12.55 | -17.33 | -22.57 | -23.67 |
| Normalized Diluted EPS | -2.81 | -5.12 | -8.20 | -11.48 | -13.00 |
| Average Basic Shares Outstanding | 6.41M | 6.40M | 6.40M | 6.40M | 6.29M |
| Average Diluted Shares Outstanding | 6.41M | 6.40M | 6.40M | 6.40M | 6.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
